Inside This Edition
1 Message from the Chief
2 Pittsburgh Liver Research Center Obtains Digestive Diseases Research Core Center (DDRCC) Designation
3 UPMC Center for Liver Diseases at The Liver Meeting 2019
4 When to Refer Your Patient for a Liver Transplant and the Benefits of Living Donation
6 Next Generation Sequencing (NGS) of Biliary Specimens improves Pre-Operative Detection and Management of Malignant Bile Duct strictures
8 Division Updates and CME Courses
9 The 2019 Annual Update in Medical Hepatology.
10 Malignant Vascular Tumor of the Liver: A Cause of Liver Failure

Message From the Chief

It was a cold December day in St. Petersburg when a blindfolded Fyodor Dostoevsky was about to be executed. The men were taken into the square, tied to pillars, and blindfolded. As the rifles were loaded, raised and aimed, a messenger arrived on horseback waving a white flag and telling the armed men to stop the execution, on direct orders from the Tsar. This was not a show of mercy. It had all been planned. Every last detail — from the blindfolds to the firing squad, to the extraordinarily convenient last-minute messenger — had been pre-arranged in a twisted form of psychological torture.

A friend of mine experienced a similar event, though in a modern medical context. The initial diagnosis based on CT was stage IV kidney cancer with bone metastases. After seven different scans and various organ biopsies, including a drilled biopsy from the os pubis, all tissue samples were negative for malignancy. The PET-CT scan was also negative. Finally, after a radiologist eradicated all the colors from the PET-CT, a reprise: Paget’s Disease, a benign sclerotic bone disease. Like Dostoyevsky, at the last minute, while contemplating mortality with profound fear — saved.

Being a physician is both spiritually and financially rewarding. Instances where you have made a difference by correctly assessing a problem and providing a solution are recognizable. It’s easy to take those moments for granted. Prescribing a PPI, detecting a cancer in the setting of iron deficiency, or even diagnosing a less common condition, such as achalasia, can be obvious to the initiated. Of course, for a patient who has no insight other than the problem they are experiencing, our analysis, investigation, and rendering of a solution can be perceived as miraculous, meritng substantial gratitude and admiration. While administering the right test and right treatment may often be routine, there is no escaping the humbling feeling of how little we know and how complex a machine the body is. A recent study estimated that about five percent of outpatient U.S. adults experience diagnostic errors, defined as missed opportunities to make a correct or timely diagnosis. Over half of these included the possibility of harm. A Johns Hopkins study in 2013, based on 35 million hospitalizations, estimated that 250,000 deaths stemmed from medical error, making medical error the third leading cause of death.

For Dostoevsky or for my friend, how does one react to the trauma? A near death experience is a form of psychological torture that can induce depression, anxiety and PTSD. Alternatively, one can rebound from a death sentence with a renewed lease on life, maximizing every moment, living life with gusto and joy, and loving every minute of what you thought you’d never have.

Dostoevsky boils down these two approaches in the novel The Brothers Karamazov, published shortly before his death, into the conflict between faith and doubt. Faith for him involved belief in God, which led to a love of mankind, kindness, forgiveness, and a devotion to goodness. Doubt referred to skepticism, which lent itself to the rejection of morality and an inner coldness and despair.

As physicians, a medical mistake, complication, or misadventure mirror all setbacks in life. All we can do after falling off the horse is get back on and try to do better. But getting back on must include rigorous attempts to understand and avoid making the same mistake. That is the essence of research!

It is my great pleasure to present another edition of Digest, where we share our research, and our attempts to learn and do better. Thanks for joining us.

In good health,

Robert E. Schoen, MD, MPH
Professor of Medicine and Epidemiology
Chief, Division of Gastroenterology, Hepatology and Nutrition
Pittsburgh Liver Research Center (PLRC) Obtains Digestive Diseases Research Core Center Designation

The Pittsburgh Liver Research Center (PLRC) has operated with support from UPMC and the University of Pittsburgh since 2016. Its mission is to bring Pittsburgh liver researchers together for meaningful collaborations and to build infrastructure to support their research with cutting-edge technology. The Digestive Diseases Research Core Center (DDRCC) designation from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) serves as validation for the high-quality work being done at the PLRC, and this honor will help to further the legacy of liver research and care in the Pittsburgh area.

Sadarshan (Paul) Singh Monga, MD is the founding director of the Pittsburgh Liver Research Center and is an endowed research chair as well as the vice chair for the Division of Experimental Pathology at the University of Pittsburgh. He serves in leadership roles in the American Society for Investigative Pathology (ASIP) and American Association for the Study of Liver Diseases (AASLD). Dr. Monga is the editor-in-chief of Gene Expression and is an associate editor for the American Journal of Pathology, Annual Review of Pathology, and Seminars in Liver Disease. He is also the assistant dean and co-director of the Medical Scientific Training Program of the University of Pittsburgh since 2016. Its mission is to bring Pittsburgh liver researchers together for meaningful collaborations and to build infrastructure to support their research with cutting-edge technology. The Digestive Diseases Research Core Center (DDRCC) designation from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) serves as validation for the high-quality work being done at the PLRC, and this honor will help to further the legacy of liver research and care in the Pittsburgh area.

The PLRC’s designation as a Core Research Center is an honor that only 20 research centers in the United States can claim. This designation and the associated five-year grant allow the PLRC to be sustainable and ensure that this research will continue to benefit patients with liver disease.

“This application required a Herculean effort from PLRC leadership, and the PLRC is honored to have received this designation after only its first application,” said Dr. Monga.

The PLRC also recognizes the incredible history of advanced liver research and clinical care within the broader Pittsburgh community, a community that the PLRC brings together and provides with important resources. To achieve the NIDDK designation, a center must have a history of integrating, coordinating, and fostering interdisciplinary collaboration among established investigators, who themselves must conduct high-quality research on digestive and liver diseases. The PLRC’s members are recognized for their excellent research, which is enhanced by Pittsburgh’s patient population and innovative research history.

Liver Research and Care in Pittsburgh

For some time, Pittsburgh has been at the forefront of liver research. The country’s first liver transplant program and first immunosuppressant therapies were developed in Pittsburgh through the work of Dr. Thomas E. Starzl, namesake for the Thomas E. Starzl Transplantation Institute. His innovative work created a platform that helped to draw researchers to the city.

especially those interested in immunology and liver transplantation, as well as researchers interested in regenerative medicine, stem cells, artificial liver devices, and the reparative qualities of the liver.

Other strengths of Pittsburgh research include the pathological diversity and sheer volume of liver patients in the area. The greater metro area has a high incidence of many advanced liver conditions, including chronic liver injury due to alcohol and nonalcoholic liver diseases in adults and a high occurrence of liver tumors. Many adult and pediatric patients also present with the black boxes of liver diseases, such as primary biliary cholangitis and primary sclerosing cholangitis, and even rarer diseases, such as progressive familial intrahepatic cholestasis (a disease more common in Old Order Amish communities), alpha-1 antitrypsin deficiency, and other monogenic disorders. Researchers are attracted to the ability to study the deeper mechanisms of these complex liver diseases, as well as liver functionality and regenerative capacities.

Until now, researchers from the University of Pittsburgh and UPMC have worked in relative isolation in many departments (e.g., pediatrics, surgery, medicine, and pathology), in addition to specialized institutes including UPMC Hillman Cancer Center and McGowan Institute for Regenerative Medicine. The primary goal of the PLRC is to bring these incredible researchers together in collaboration and to offer them cutting-edge research tools.

Research Areas and Scientific Service Cores

to foster translational science, dynamic dialogue, and enhanced collaboration, the PLRC hosts monthly group round tables covering three topics: chronic liver injury, liver tumorigenesis, and regenerative medicine, which form the research base of the PLRC. During these roundtables, a researcher and a clinician are paired together by topic and are allowed to present and discuss the topics from their perspective. Additional education occurs through invited seminars from visiting professors with expertise in specific areas of liver health and disease. These educational activities are coordinated by PLRC’s Enrichment Program under the leadership of Kari Njiek-Bower, MBA, MD. Members also have free or low-cost access to a variety of scientific resources, an infrastructure that the PLRC has developed through four unique cores:

1. The Advanced Cell Tissue and Imaging Center, directed by Donna Stolz, PhD, supports liver research through the Center for Biologic Imaging, one of the largest optical imaging centers in the country. This center provides our members access to cutting-edge optical imaging equipment, with priority given to funded collaborations and joint outputs.

2. The Biospecimen Repository and Processing Core provides a centralized location for investigators to request tissues, cells, and tissue microarrays. A tissue utilization committee considers each request for tissues and determines specimen distribution based on project relevance and feasibility. This committee is led by David Geller, MD, co-director of the UPMC Liver Cancer Center, Richard L. Simmons Professor of Surgery, and Aatur Singh, MD, PhD, a leading collaborator from the Department of Pathology.

3. The Genomics and Systems Biology Core provides primary genome and data analysis services to researchers seeking insight at the levels of RNA and DNA. Directed by Jianhua Lue, MD, PhD, and Takis Benos, PhD, this core provides integral technological resources for research and works to build a precision-medicine, biomarker-centered approach to liver disease treatments.

4. The Clinical Component is an essential element of the PLRC that serves as its conduit for translation and commercialization of research. The Clinical Component is led by Ramon Bataller, MD, PhD. Dr. Bataller and colleagues have assembled a team of clinicians from various disciplines to offer a direct clinical perspective to researchers at any stage in their project. This helps investigators to select clinically meaningful end-points, design a clinically consequential methodology, and to select appropriate human biopsies.

Each core group has contributed to the success of the PLRC, and its directors are pivotal to this DDRCC designation and the success of this endeavor.

“I’d like to offer a special thanks to Dr. Bataller and to each of the core directors for their leadership and support to obtain this grant,” said Dr. Monga.

The Future of the PLRC

For the continued health of any research community, some percentage of resources must be dedicated to the pursuit of preliminary data in novel studies and to the development of new research talent within the community’s networks. Under the direction of Gavin Antsel, PhD and Paul Monga, MD, the PLRC funds novel initiatives and new investigators who are pursuing liver-related research through the Pilot and Feasibility grant funding program. The PLRC has supported many University of Pittsburgh investigators from a variety of disciplines through annual, longitudinal mentoring.

The PLRC offers exciting new insights for investigators and clinicians, and our patients are provided with consequent new hope to overcome their diseases. The PLRC underscores that young researchers can advance their careers in Pittsburgh through program support for preliminary investigations. Critical PLRC mission components include the ability to establish proactive liver research leaders and resources and to invest in the future of liver care in Pittsburgh and around the world. For more information about the PLRC and its innovative work, visit LiverCenter.pitt.edu.

UPMC Center for Liver Diseases at The Liver Meeting 2019

Friday, Nov. 8 to Tuesday, Nov. 12

The UPMC Center for Liver Diseases was well represented at The Liver Meeting® 2019. Our physicians discussed a wide variety of clinical and basic science topics on every day of the conference.

Saturday, Nov. 9, we hosted a reception in collaboration with the Thomas E. Starzl Transplantation Institute and the Pittsburgh Liver Research Center. Thank you to all who attended and all who participated in our presentations. Please join us again next year.

For more information about our presence at the AASLD annual meeting, visit the Featured News section at UPMCPhysicianResources.com/GL.
When to Refer Your Patient for a Liver Transplant and the Benefits of Living Donation

In a short period of time, transplantation has progressed from an experimental procedure to the standard of care for patients with end-stage organ failure. With the establishment of the country’s first liver transplant program in 1981, to performing our first adult living-donor liver transplant in 1999, to becoming one of the top and most experienced programs in the country for living donor transplants, physicians and researchers at UPMC have refined new therapies, giving hope to patients across the country and around the world.

**CURRENT STATUS OF LIVER TRANSPLANT IN THE U.S.**

![Graph showing the number of liver transplant procedures performed in the U.S. from 2006 to 2018.](image)

**When to Refer for a Liver Transplant**

Referral for a liver transplant should be initiated early, before the patient is too sick to be considered an appropriate candidate for transplantation. Early referral allows our team to address and resolve any pretransplant complications while the patient’s liver disease is relatively controlled. General indications for when to refer include continued progress of the patient’s disease despite maximized medical therapies, development of a life-threatening complication such as hepatocellular carcinoma (HCC), or an increasingly unsatisfactory quality of life.

The MELD score determines how urgently a patient requires a liver transplant based on the likelihood of death within a three-month period. A MELD score of 10 or higher is a clinical indication of liver dysfunction. Patients with higher MELD scores have worse short-term prognoses and are given higher priority for the next available deceased-donor liver.

A patient’s MELD score is based on:

- Serum creatinine
- Bilirubin
- International normalized ratio (INR)

**Indications for a Liver Transplant**

A patient with liver disease and a high risk of decomposition is a candidate for a liver transplant. A candidate for liver transplantation may suffer from:

- Hepatitis C
- Hepatitis B
- Alcoholic liver disease
- Nonalcoholic steatohepatitis or fatty liver disease
- Primary liver cancers
- Primary biliary cirrhosis
- Autoimmune hepatitis
- Primary sclerosing cholangitis
- Acute liver disease from toxins including acetaminophen/Tylenol
- Alpha-1 Antitrypsin deficiency
- A failed prior liver transplant
- Polyycyctic disease
- Hemochromatosis
- Veno-occlusive disease
- Wilson’s disease

A miracle of modern medicine, liver transplantation is the only definitive treatment for patients with end-stage liver disease. The one-year survival rate following transplantation is the only definitive treatment for patients with end-stage liver disease. The one-year survival rate following transplantation ranges from 87 to 93 percent in the country for liver transplant. Many patients have a 15 to 20 percent chance of succumbing to their disease before making it to transplant.

**TRANSPLANT REFERRAL PROCESS**

1. **Initial Referral:**
   - Transplant team receives initial referral
   - Referring physician receives an email with additional information
2. **Preliminary Transplantation Evaluation/MELD Score Ranking:**
   - Referral team reviews patient’s medical history
   - Preliminary assessment is performed by transplant team to address and resolve any pretransplant complications
   - MELD score is calculated
3. **Financial Management/Wait List:**
   - Referral to financial management office
   - Wait-list assessment is performed by transplant team
4. **Transplantation:**
   - Referral to transplant team
   - Assessment of patient’s medical history and current condition
   - Set date for transplant procedure
5. **Post-Op Medical Management:**
   - Referral to transplant team
   - Post-transplant care

**When to Refer for a Liver Transplant**

- Identifying patients with end-stage liver disease who will benefit from transplantation
- Timely referral of those patients to the transplantation center
- Assisting in the coordination of specialists in pretransplant evaluation
- Collaborating with the transplant team in the long-term care and posttransplant care of the patient

As an integral member of the patient care team, the referring physician will be continually updated about the patient’s progress by a member of the transplant team. Continuous interaction with the transplant team can range from in-person and telephone interactions to email communications or teleconference sessions for physicians located remotely.

**About UPMC’s Liver Transplant Program**

One of the oldest and largest liver transplant programs in the country, UPMC has performed more than 6,000 adult liver transplants and more than 400 adult living-donor liver transplants. We believe that liver transplantation should be an option for any patient with end-stage liver disease who no longer experiences results with medical therapy and want a second chance at life.

Additionally, UPMC works with hospitals that have an existing liver transplant program and want to provide patients the option of a living-donor liver transplant. When partnering with another hospital, UPMC provides pre- and postsurgery consultation and training for clinicians, while the surgery itself occurs at UPMC.

For more information about our program and how to begin the referral process, visit [UPMC.com/LiverTransplantReferral](UPMC.com/LiverTransplantReferral).
The poor performance of current preoperative methods for differentiating between malignant and benign biliary strictures results in some patients undergoing surgical resection despite having benign strictures. Alternatively, this can result in a delay in the diagnosis of biliary cancer. Seeking a solution, Aatur Singh, MD, PhD, and Adam Silvka, MD, PhD, developed a targeted NGS assay called BiliSeq. Testing endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens against this assay offers clinicians a more reliable diagnosis compared to standard methods.

Aatur Singh, MD, PhD, is an associate professor of pathology and a member of both the Gastrointestinal Pathology Center of Excellence and the Division of Molecular and Genomic Pathology. His research has a translational focus in the areas of gastrointestinal, pancreatic, hepatobiliary, and peritoneal pathology.

Adam Silvka, MD, PhD, is the medical director of the UPMC Molecular Diagnostics Center and is the associate chief of Clinical Affairs for the Division of Gastroenterology, Hepatology and Nutrition, where he also serves as a professor of medicine. His research interests include noninvasive diagnosis of pancreaticobiliary cancer, the development and testing of new drugs and devices used during ERCP, and the development of new strategies to treat pancreatic and pancreatic cancer.

Benign biliary strictures are typically due to conditions such as sclerosing cholangiopathy, iatrogenic injury, and infection, while malignant strictures are related to carcinomas arising from the pancreato bile duct cell, ampulla of Vater, and liver cancers. The preferred methods for pathologic confirmation during endoscopic retrograde cholangiopancreatography (ERCP) are bile duct brushings and forceps biopsies, but the sensitivity of these approaches to detect malignancy can vary from eight to 67 percent. Several ancillary detection techniques have been developed, including digital image analysis, FOBT mutation testing, and multicolor fluorescence in situ hybridization (FISH), but these methods also fail to produce reliable diagnoses due to the wide variance in sensitivity and, in the case of the latter method, a propensity for subjective interpretation errors, which can only be avoided by an experienced pathologist performing labor intensive work.

Distinguishing between the two is difficult, especially because certain conditions, like primary sclerosing cholangitis (PSC), are associated with benign strictures but are also associated with an increased risk of bile duct cancer and may harbor pre-cancerous changes. The failure of current diagnostic methods for malignant biliary strictures often leads to repeated ERCP procedures and delayed clinical decisions that risk disease progression, and even more alarming, can lead to a high percentage of patients undergoing an unnecessary surgical resection. A more reliable method is required for preoperative diagnosis of malignant biliary duct strictures, and this strictures. For clinicians, this testing can grant the ability to avoid unnecessary resections and to make evidence-based clinical decisions before the disease progresses. Our results also have implications for the growing body of literature around precision medicine. BiliSeq testing identified two patients with ERBB2 amplifications, a genomic alteration known to respond well to trastuzumab in conjunction with standard first-line chemotherapy. Both patients exhibited measurable radiographic responses and normalization of serum CA19-9, and both are currently alive and well thanks to the ability of NGS to provide a personalized, targeted treatment option. To learn more about these patients, visit UPMPCPeerResources.com/GI and click on Gastroenterology Digest, Fall 2019.

NGS and Its Use in Previous Studies of Biliary Strictures

Sequencing of the human genome was once an expensive, time-consuming process, but the advent of NGS and the introduction of novel molecular diagnostics have created unparalleled opportunities for low-cost use of DNA sequencing in clinical and research environments. Consequently, our understanding of the genomic landscape of neoplasms arising in, or secondarily involving, the bile duct system has improved at an incredible pace in recent years. These innovations have played a pivotal role in recent research studying the ability to distinguish between malignant and benign strictures. Banok et al. published the results of an NGS assay that was used to test a retrospective cohort of patients and found a sensitivity of 81 percent. However, this study tested only 16 patients, did not evaluate biliary brushing specimens, and used DNA extracted from Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks for sequencing, resulting in such a low-quality level of DNA that it had to be enriched before analysis. A more comprehensive assessment of NGS testing on bile duct specimens was reported by Dudley et al., which studied a cohort of 73 bile duct and eight main pancreatic duct brushing specimens, finding a sensitivity of 68 percent and a specificity of 97 percent. But even this larger study did not collect dedicated brushings for DNA isolation and extracted DNA from Cytolyt-preserved specimens. Unsurprisingly, 11 percent of their specimens had degraded to the point of failing NGS testing.

This previous literature has shown that NGS testing of bile duct specimens may have promise, but a more comprehensive study was required for definitive evaluation of the impact on patient management when genomic alterations are detected in bile duct specimens.

Methodological improvements and Results

In our study, we developed a highly sensitive, targeted NGS assay called BiliSeq in a laboratory with Clinical Laboratory Improvement Amendments certification and accreditation by the College of American Pathologists. Investigation centered on 28 genes that are commonly mutated, amplified, and/or deleted in malignant neoplasms involving the bile duct system. During an initial training cohort followed by a validation cohort, a total of 163 biliary brushings and 172 biliary biopsies were collected for pathological evaluation. Rather than relying on DNA-extraction methods from processed pathology specimens that might have reduced the yield and quality of the genome, we performed a dedicated bile duct brushing and for biopsy for each patient and submitted the resultant 160 brushings and 135 biopsies for BiliSeq testing. NGS was performed prospectively as part of clinical care with a 10-day turnaround in the UPMC Molecular & Genomic Pathology (MGP) Laboratory. We then compared the results of NGS testing with the results of diagnostic pathology of 145 surgically resected specimens or biopsy specimens with the results of further clinical evaluations on 75 of the patients. BiliSeq was found to have a sensitivity of 73 percent and a specificity of 100 percent, an improvement over pathological evaluation alone for detecting at least high-grade bile duct dysplasia involving the bile duct. The combination of both pathological and BiliSeq testing brought sensitivity up to an incredible 83 percent while maintaining a specificity of 99 percent.

A preliminary observation from this study is the striking improvement in sensitivity that BiliSeq allowed for patients with PSC. These patients' strictures are typically caused by inflammation, so it is often challenging to procure a sample, and pathologic evaluation usually produces unreliable diagnoses. Routine cytologic evaluation tested at an eight percent sensitivity for PSC patients, but BiliSeq achieved a sensitivity of 83 percent for at least high-grade biliary dysplasia. This is compelling evidence to further explore the potential of BiliSeq to improve clinical outcomes for this high-risk patient population.

Clinical implications of Results

These results highlight the diagnostic applicability of NGS-based assays to ERCP-obtained biliary specimens in the early detection and management of patients with indeterminate bile duct strictures. For clinicians, this testing can grant the ability to avoid unnecessary resections and to make evidence-based clinical decisions before the disease progresses.

For a full list of references, visit UPMCPhysicianResources.com/GI and click on Gastroenterology Digest, Fall 2019.

References

1. Singh AD, Nishimura K, Chaturvedi S, Pelletier GS, Khattak A, Rabonowitz M, Tran R, Burchette RL, Sato M, Kim Y, Kumar A, Kazmi S, Holcomb J, Lee J. Aatur Singhi, Adam Slivka, MD, PhD, and Adam Slivka, MD, PhD, developed a targeted NGS assay called BiliSeq. Testing endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens against this assay offers clinicians a more reliable diagnosis compared to standard methods.
Thank you to all who attended the 2019 Annual Update in Medical Hepatology. This CME program was intended for experts in hepatology, gastroenterology, and abdominal and general surgery, referring primary care physicians, and other health care professionals with an interest in the treatment and latest research for liver disease.

At the event, our experts presented recent advancements and new innovations in highly active research areas. Topics included:

- An Integral Approach to Treat Alcohol-Induced Liver Disease
- Recent Advances in the Management of NAFLD
- Management of Complications of Cirrhosis
- Living-Donor Liver Transplant: the UPMC Experience
- Current Trends in Liver Transplantation

For more information, visit the Featured Events section at UPMCPhysicianResources.com/GI. Please join us again next year.
Malignant Vascular Tumor of the Liver: A Cause of Liver Failure

Two years ago, while on his honeymoon, a 36-year-old male presented with spontaneous splenic rupture and liver lesions concerning for angiosarcoma. He did not respond to doxorubicin. He was later diagnosed with hepatosplenic T-cell lymphoma (HSTCL) on repeat liver biopsy and responded to chemotherapy including hyper-CVAD. He underwent stem-cell transplant (SCT) that was complicated by graft-versus-host disease and CMV viremia, although he eventually achieved remission.

The patient presented with two months of increasing abdominal pain and distention. A CT scan was notable for hepatomegaly and numerous lesions involving the liver, right kidney, and sacrum (see Figure 1). Bone marrow biopsies were unrevealing for malignancy. His liver function declined, and he was referred for liver transplant evaluation.

On exam, the patient was jaundiced and demonstrated massive hepatomegaly and anasarca. Labs revealed renal insufficiency, anemia, thrombocytopenia and coagulopathy, total bilirubin 33 mg/dL, AST 1336, ALT 378, and alkaline phosphatase 333 U/L. His course was complicated by rapid deterioration due to a large paraspinal hematoma with hemothorax and hemothorax (requiring hepatic artery embolization), toxic epidermal necrolysis, disseminated intravascular coagulation, and ultimately, multiorgan failure with septic shock. Given concerns for an aggressive malignancy, he was not deemed to be a candidate for transplant.

Postmortem analysis revealed a liver measuring 30 x 25 x 20 cm, weighing 7.0 kilograms with 90 percent of hepatic parenchyma composed of blood-filled vascular masses and confluent dark red hemorrhagic tumor nodules. Review of previously obtained biopsies by multiple pathology specialists diagnosed a malignant vascular tumor of the liver, representing either a hepatic angiosarcoma or hemangioendothelioma.

Malignant Vascular Tumors of the Liver

Malignant vascular tumors of the liver include hepatic angiosarcomas (HAS), epithelial hemangioendotheliomas (EH), and hemangiopericytomas. HAS is a high-grade tumor that can progress rapidly with metastases to areas including the spleen, lymph nodes, lungs, bone, and adrenal. It typically presents in patients 50 to 70 years of age and is more common in men. HAS is characterized by poorly defined hemangiomas and neovascular nodules that are hypodense and do not enhance with contrast on imaging. These tumors may be associated with certain exposures, such as vinyl chloride, arsenic, and thorium. Clinical presentation may vary, and possible symptoms include abdominal pain, jaundice, ascites, and, rarely, Budd-Chiari syndrome. Fifteen percent of HAS patients present initially with acute spontaneous hemoperitonitis due to nodule rupture. Causes of death include liver failure and intra-abdominal bleeding. Microangiopathic hemolytic anemia and thrombocytopenia may result from damage when blood cells pass through tumor vasculature. On pathology, characteristic findings include variably differentiated tumor endothelial cells with severe nuclear atypia and frequent mitoses along dilated sinusoids. HAS and HE have been included in the World Health Organization classification of tumors of the digestive system. They are characterized by neoplastic cellular infiltration with thrombocytopenia and purpura.

Surgical resection may be performed for HAS, but even with complete resection, patient survival is less than one year. Because of a high recurrence rate and poor survival post-transplant, liver transplantation is not recommended. Various chemotherapeutic regimens have been tested (including doxorubicin, ifosfamide, and paclitaxel), but there has been no proven effectiveness with these therapies.

Epithelial hemangioendotheliomas (EH) are less common (incidence of less than 0.1 per 100,000) than HAS and are low-grade, although they frequently metastasize to the lungs, lymph nodes, peritoneum, bone, and spleen. Most commonly, EH affects individuals 40 to 50 years of age and is characterized by cellular infiltration of tumor cells in sinusoids and intraluminal veins. Presentation can range from absence of symptoms to portal hypertension or hepatic failure with scleroderma or rapidly progressive disease. However, a multifocal tumor with varying sized nodules is typical. In contrast to HAS, the tumor periphery may enhance with contrast and may resect the liver capsule with calcifications in 20 percent of cases. Pathology is characterized by necrotic cellular infiltration with epithelial-like cells of sinusoids and intraluminal veins. Kaposiform hemangioendotheliomas (KHE) is a rare, locally aggressive tumor more frequently seen in children. KHE may be associated with Kasabach-Merritt phenomenon, or consumptive coagulopathy with intravascular fibrin deposition with thrombocytopenia and purpura.

References:

The Division of Gastroenterology, Hepatology and Nutrition is honored and proud to welcome the following June 2019 gastroenterology & hepatology fellow graduates as GI colleagues:

Jeffrey Duerer, MD: Assistant Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition, UPMC Digestive Disorders Center, and the VA Pittsburgh Healthcare System – Pittsburgh, PA
Matthew Klinge, MD: Gastroenterologist, Bayfront Digestive Diseases at UPMC Hamot – Erie, PA
Bassem Matta, MD: Advanced Therapeutic Endoscopy Fellow, New York University Langone Health – New York, NY
R. Warren Sands, MD, PhD: Continuing Studies as an Advanced ABIM Research Pathway Fellow – Division of Gastroenterology, Hepatology and Nutrition – Pittsburgh, PA

Debbie Cheng, MD, is a gastroenterology fellow, Year II, in the Division of Gastroenterology, Hepatology and Nutrition.

Figure 1. Hepatomegaly (measuring 36.5 cm craniocaudally, seen on left) with numerous confluent hypodense lesions.
The Division of Gastroenterology, Hepatology and Nutrition is one of the leading centers for gastrointestinal clinical care and research in the country.

The UPMC Digestive Disorders Center is a comprehensive care program for patients that covers the full range of digestive health conditions, including:

- Inflammatory Bowel Diseases
- Cancer Prevention and Treatment
- Functional Bowel Disorders
- Hepatic Disorders and Diseases
- Pancreatic and Biliary Diseases
- Nutrition Support

The Division also includes eight Centers of Excellence that provide specialized care for complex cases and conduct research on numerous fronts to better understand, and develop treatments for, disorders and diseases of the gastrointestinal and related systems.

Centers of Excellence

- Pancreas and Biliary Center
- Center for Liver Diseases
- Center for Intestinal Health and Nutrition Support
- Center for Women's Digestive Health
- IBD Center and UPMC Total Care-IBD
- GI Cancer Prevention and Treatment Center
- Neurogastroenterology and Motility Center
- About UPMC

A $20 billion health care provider and insurer, Pittsburgh-based UPMC is inventing new models of patient-centered, cost-effective, accountable care. The largest nongovernmental employer in Pennsylvania, UPMC integrates 87,000 employees, 40 hospitals, 700 doctors' offices and outpatient sites, and a more than 3.5 million-member Insurance Services Division, the largest medical insurer in western Pennsylvania. In the most recent fiscal year, UPMC contributed $1.2 billion in benefits to its communities, including more care to the region's most vulnerable citizens than any other health care institution, and paid $587 million in federal, state, and local taxes. Working in close collaboration with the University of Pittsburgh Schools of the Health Sciences, UPMC shares its clinical, managerial, and technological skills worldwide through its innovation and commercialization arm, UPMC Enterprises, and through UPMC International. UPMC Presbyterian Shadyside is ranked #1 in Pennsylvania and #15 in the nation, and is one of only nine hospitals ranked in the nation's top 20 of America’s Best Hospitals for 10 years in a row by U.S. News & World Report. UPMC Children’s Hospital of Pittsburgh is ranked in the nation's top 10 of America’s Best Children’s Hospitals by U.S. News & World Report. For more information, go to UPMC.com.